New approach could expand CAR T therapy from blood cancers to solid tumors

New approach could expand CAR T therapy from blood cancers to solid tumors. Researchers at the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute report that combining CAR T cell immunotherapy with a targeted radiopharmaceutical significantly improved tumor regression in preclinical models of neuroblastoma, a rare and aggressive cancer that usually forms in nerve tissue outside the brain and primarily affects children.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: Researchers at the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute report that combining CAR T cell immunotherapy with a targeted radiopharmaceutical significantly improved tumor regression in preclinical models of neuroblastoma, a rare and aggressive cancer that usually forms in nerve tissue outside the brain and primarily affects children. The findings were published in Cell Reports Medicine.

• Ponto de atenção: approach.
• Ponto de atenção: could.
• Ponto de atenção: expand.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.